A Phase II Evaluation of Weekly Paclitaxel (NSC 673089) and Celecoxib (Celebrex, NSC 719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer.

Trial Profile

A Phase II Evaluation of Weekly Paclitaxel (NSC 673089) and Celecoxib (Celebrex, NSC 719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2013

At a glance

  • Drugs Celecoxib (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top